Molecular targeted drugs are too simple for common cancers, says UK researcherBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c153 (Published 11 January 2010) Cite this as: BMJ 2010;340:c153
- Rebecca Coombes
The focus on drugs targeted at specific molecules in the development of new cancer treatments may be misguided, claims a senior UK cancer researcher, who argues that many common cancers are too complex for this approach to be successful.
Stephen Neidle, director of the centre for cancer medicines at the University of London’s School of Pharmacy, said that billions of pounds had been spent developing molecular targeted drugs for cancer but that these have had very limited success in the most common forms of the disease, such as prostate and colorectal cancer.
He said the approach had been encouraged after the success …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial